Poniard Pharmaceuticals, Inc.
PARD · OTC
9/30/2011 | 6/30/2011 | 3/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.05 | 0.04 | 0.06 |
| FCF Yield | -22.80% | -12.30% | -8.95% | -19.23% |
| EV / EBITDA | -2.08 | -3.30 | -6.46 | -6.04 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | – | 0.62 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1.43% | 16.96% | 59.81% | -30.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.59 | 1.33 | -0.07 |
| Interest Coverage | -162.96 | -166.87 | -134.67 | -10.12 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |